Search results for " plasminogen activator"

showing 10 items of 77 documents

Annexin A2-Mediated Plasminogen Activation in Endothelial Cells Contributes to the Proangiogenic Effect of Adenosine A2A Receptors

2021

Adenosine A2A receptor mediates the promotion of wound healing and revascularization of injured tissue, in healthy and animals with impaired wound healing, through a mechanism depending upon tissue plasminogen activator (tPA), a component of the fibrinolytic system. In order to evaluate the contribution of plasmin generation in the proangiogenic effect of adenosine A2A receptor activation, we determined the expression and secretion of t-PA, urokinase plasminogen activator (uPA), plasminogen activator inhibitor-1 (PAI-1) and annexin A2 by human dermal microvascular endothelial cells stimulated by the selective agonist CGS-21680. The plasmin generation was assayed through an enzymatic assay a…

0301 basic medicineFarmacologiaAngiogenesisPlasminmedicine.medical_treatmentVasodilatadorsAdenosine A2A receptorRM1-950030204 cardiovascular system & hematologyTissue plasminogen activatormicrovascular endothelial cells03 medical and health scienceschemistry.chemical_compound0302 clinical medicineFibrinolysismedicinePharmacology (medical)urokinase plasminogen activatorPharmacologytissue plasminogen activatorChemistryBrief Research Reportannexin A2adenosine receptorsCell biology030104 developmental biologyPlasminogen activator inhibitor-1plasminogen activator inhibitor-1Therapeutics. PharmacologyPlasminogen activatorProteïnesAnnexin A2medicine.drug
researchProduct

Lipoprotein receptor loss in forebrain radial glia results in neurological deficits and severe seizures.

2020

The Alzheimer disease-associated multifunctional low-density lipoprotein receptor-related protein-1 is expressed in the brain. Recent studies uncovered a role of this receptor for the appropriate functioning of neural stem cells, oligodendrocytes, and neurons. The constitutive knock-out (KO) of the receptor is embryonically lethal. To unravel the receptors' role in the developing brain we generated a mouse mutant by specifically targeting radial glia stem cells of the dorsal telencephalon. The low-density lipoprotein receptor-related protein-1 lineage-restricted KO female and male mice, in contrast to available models, developed a severe neurological phenotype with generalized seizures duri…

0301 basic medicineMaleEpendymoglial CellsBiology03 medical and health sciencesCellular and Molecular NeuroscienceEpilepsyMice0302 clinical medicineProsencephalonSeizuresmedicineAnimalsReceptors LipoproteinLipoprotein receptor-related proteinmedicine.diseaseNeural stem cellLipoproteins LDL030104 developmental biologymedicine.anatomical_structureNeurologyAstrocytesTissue Plasminogen ActivatorForebrainFemaleSynaptic signalingStem cellPostsynaptic densityNeuroscience030217 neurology & neurosurgeryAstrocyteGliaREFERENCES
researchProduct

Measurement of Bradykinin Formation and Degradation in Blood Plasma: Relevance for Acquired Angioedema Associated With Angiotensin Converting Enzyme …

2020

Bradykinin (BK)-mediated angioedema (AE) states are rare acquired or hereditary conditions involving localized edema of the subcutaneous and submucosal tissues. Citrated plasma from healthy volunteers or patients with hereditary angioedema (HAE) with normal level of C1-inhibitor (C1-INH) was used to investigate pathways of BK formation and breakdown relevant to AE physiopathology. The half-life of BK (100 nM) added to normal plasma was 34 s, a value that was increased ~12-fold when the angiotensin converting enzyme (ACE) inhibitor enalaprilat (130 nM) was added (enzyme immunoassay measurements). The BK half-life was similarly increased ~5-fold following 2 daily oral doses of enalapril malea…

0301 basic medicinemedicine.medical_specialtykallikreinsPlasminBradykininTissue plasminogen activator03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicineB2 receptorsOriginal ResearchplasminFactor XIIlcsh:R5-920tissue plasminogen activatorAngioedemabiologyhereditary angioedema with normal C1 inhibitor levelAngiotensin-converting enzymeGeneral MedicineKallikreinmedicine.disease030104 developmental biologyEndocrinology030228 respiratory systemchemistryHereditary angioedemabiology.proteinMedicinemedicine.symptombradykininlcsh:Medicine (General)medicine.drugFrontiers in Medicine
researchProduct

Coronavirus Disease 2019–Associated Coagulopathy

2021

Patients with the severe form of coronavirus disease 2019 (COVID-19) have been frequently found to suffer from both arterial and venous thrombotic events due to the perpetuation of a hypercoagulable state. This phenomenon, termed COVID-19-associated coagulopathy (CC), is now considered a major component of the pathophysiology of this novel infectious disease, leading to widespread thrombosis. While at first, the vascular insults may be limited to the pulmonary microvasculature, as the disease progresses, systemic involvement occurs, culminating in distant organ thrombosis and multi-organ dysfunction syndrome. In this review article, we discuss recent insights into the pathophysiologic mecha…

ARDSPAI-1 Plasminogen Activator Inhibitor 1VTE venous thromboembolismDiseaseReview030204 cardiovascular system & hematologyCoronavirus Disease 20190302 clinical medicineCoagulopathy030212 general & internal medicineDIC disseminated intravascular coagulationDisseminated intravascular coagulationCOVID-19 Coronavirus disease 2019DVT deep vein thrombosisGeneral MedicineBlood Coagulation DisordersThrombosisICU intensive care unitTMA thrombotic microangiopathyDisease ProgressionCoronavirus Disease 2019 COVID-19 CoagulopathyVWF von Willebrand factormedicine.medical_specialtyThrombotic microangiopathyACE2 angiotensin-converting enzyme 2SARS-CoV-2 severe acute respiratory syndrome coronavirus 203 medical and health sciencesmedicineCoagulopathyHumansIntensive care medicineLY30 lysis at 30 minutesARDS acute respiratory distress syndromeHemostasisNO nitric oxideCoagulationbusiness.industrySARS-CoV-2COVID-19Thrombosismedicine.diseasetPA tissue plasminogen activatorReview articleIL interleukinCoronavirusVascular DisorderPE pulmonary embolismTF tissue factorbusinessCC COVID-associated coagulopathyMayo Clinic Proceedings
researchProduct

Systematic Analysis of Combined Thrombolysis Using Ultrasound and Different Fibrinolytic Drugs in an in Vitro Clot Model of Intracerebral Hemorrhage.

2021

Adequate removal of blood clots by minimally invasive surgery seems to correlate with a better clinical outcome in patients with intracerebral hemorrhages (ICHs). Moreover, neurotoxic effects of recombinant tissue plasminogen activator have been reported. The aim of this study was to improve fibrinolysis using an intra-clot ultrasound application with tenecteplase and urokinase in our established ICH clot model. One hundred thirty clots were produced from 25 or 50 mL of human blood, incubated for different periods and equipped with drainage, through which an ultrasound catheter was placed in 65 treatment clots for 1 h, randomly allocated into three groups: administration of ultrasound, admi…

Acoustics and UltrasonicsMechanical Thrombolysismedicine.medical_treatmentUltrasonic TherapyBiophysicsTenecteplase030204 cardiovascular system & hematologyIn Vitro Techniques03 medical and health sciences0302 clinical medicineFibrinolytic AgentsFibrinolysismedicineHumansRadiology Nuclear Medicine and imagingThrombolytic TherapyCerebral HemorrhageIntracerebral hemorrhageUrokinaseRadiological and Ultrasound Technologybusiness.industryUltrasoundThrombosisThrombolysismedicine.diseaseCombined Modality TherapyUrokinase-Type Plasminogen ActivatorIn vitroCatheterAnesthesiaTenecteplasebusiness030217 neurology & neurosurgerymedicine.drugUltrasound in medicinebiology
researchProduct

Blood coagulation factor XII drives adaptive immunity during neuroinflammation via CD87-mediated modulation of dendritic cells

2016

Aberrant immune responses represent the underlying cause of central nervous system (CNS) autoimmunity, including multiple sclerosis (MS). Recent evidence implicated the crosstalk between coagulation and immunity in CNS autoimmunity. Here we identify coagulation factor XII (FXII), the initiator of the intrinsic coagulation cascade and the kallikrein–kinin system, as a specific immune cell modulator. High levels of FXII activity are present in the plasma of MS patients during relapse. Deficiency or pharmacologic blockade of FXII renders mice less susceptible to experimental autoimmune encephalomyelitis (a model of MS) and is accompanied by reduced numbers of interleukin-17A-producing T cells.…

AdultMale0301 basic medicineEncephalomyelitis Autoimmune ExperimentalMultiple Sclerosisanimal structuresT-LymphocytesScienceMedizinGeneral Physics and AstronomyKininsCoagulation Factor XIIAdaptive ImmunityBiologymedicine.disease_causeArticleGeneral Biochemistry Genetics and Molecular BiologyReceptors Urokinase Plasminogen ActivatorAutoimmunityYoung Adult03 medical and health sciencesImmune systemddc:570medicineAnimalsHumansddc:610cardiovascular diseasesNeuroinflammationAgedFactor XIIMultidisciplinaryInterleukin-17QExperimental autoimmune encephalomyelitisCell DifferentiationDendritic CellsGeneral ChemistryMiddle Agedmedicine.diseaseAcquired immune systemMice Inbred C57BL030104 developmental biologyNeuroimmunologyFactor XIIImmunologyFemaleKallikreinscirculatory and respiratory physiologyNature Communications
researchProduct

Prognostic value of soluble urokinase plasminogen activator receptor in patients presenting to the emergency department with chest pain suggestive of…

2021

International audience; INTRODUCTION: Soluble urokinase plasminogen activator receptor (suPAR) is a prognostic biomarker of cardiovascular disease. OBJECTIVES: We aimed to evaluate the early prognostic value of suPAR in patients presenting to the emergency department (ED) with chest pain suggestive of acute coronary syndrome (ACS). PATIENTS AND METHODS: In a post-hoc analysis from a multicenter study including patients with a chest pain < 6 h, suPAR concentrations at ED admission were studied according to the outcome at 30-days. RESULTS: 198 patients (median age 56 years) in whom 16% had an ACS, were included. Fifteen (7.3%) patients presented a 30-day event. At ED admission, median (IQR…

AdultMale030213 general clinical medicineAcute coronary syndromemedicine.medical_specialty[SDV]Life Sciences [q-bio]Clinical BiochemistrySoluble urokinase plasminogen activator receptorDisease030204 cardiovascular system & hematologyChest painPrognosticGastroenterologyReceptors Urokinase Plasminogen ActivatorsuPARChest pain03 medical and health sciences0302 clinical medicinePredictive Value of TestsInternal medicinemedicineHumansIn patientAcute Coronary SyndromeReceptorAgedOutcomeAged 80 and overbusiness.industryEmergency departmentGeneral MedicineEmergency departmentMiddle Agedmedicine.diseasePrognosisED30-day event3. Good health[SDV] Life Sciences [q-bio]SuPARBiomarker (medicine)Femalemedicine.symptombusinessEmergency Service HospitalBiomarkers
researchProduct

Kallikrein–kinin system and fibrinolysis in hereditary angioedema due to factor XII gene mutation Thr309Lys

2009

In a subgroup of hereditary angioedema (HAE) patients with normal C1-esterase inhibitor levels, HAE is caused by a Thr309Lys mutation in the coagulation factor XII (F12) gene. The aim of this study was to examine elements of the kallikrein-kinin system ('contact system') and the downstream-linked coagulation, complement and fibrinolytic systems in the plasma of six patients with HAE caused by the Thr309Lys mutation and healthy probands. Blood samples were taken from participants during the symptom-free interval between attacks. Samples were analyzed for activity and concentrations of components of the kallikrein-kinin system and linked enzyme systems. The mean FXII clotting activity was 90%…

AdultMalemedicine.medical_specialtyAdolescentMutation MissenseKininsCoagulation Factor XIIFactor XIIaGene mutationYoung AdultInternal medicinemedicineHumansPoint MutationHereditary Angioedema Type IIIComplement Pathway ClassicalAgedAged 80 and overFactor XIIAngioedemaChemistryFibrinolysisDextran SulfateAngioedemas HereditaryPrekallikreinPrekallikreinBlood ProteinsHematologyGeneral MedicineMiddle AgedSilicon Dioxidemedicine.diseaseEnzyme ActivationEndocrinologyAmino Acid SubstitutionChromogenic CompoundsCoagulationTissue Plasminogen ActivatorHereditary angioedemaImmunologyFemaleKallikreinsmedicine.symptomcirculatory and respiratory physiologyBlood Coagulation & Fibrinolysis
researchProduct

Increased plasminogen activator inhibitor antigen levels in diabetic patients with stable angina

1991

PAI-1 antigen, tPA antigen and thrombin - antithrombin III complexes (TAT) levels were measured in 10 males with stable angina and type-II diabetes mellitus and in 16 males with stable angina without diabetes or other risk factors (hyperfibrinogenaemia, hyperlipidaemia, diabetes, hypertension, smoking and obesity) known to increase PAI levels. Ten healthy men of equivalent age served as controls. Because only diabetics with coronary artery disease (CAD) showed a decreased fibrinolytic capacity, a second study was performed on the 16 non-diabetic CAD patients to determine whether submaximal workload induces significant changes of tPA and PAI levels. TAT levels were increased in CAD, and sign…

AdultMalemedicine.medical_specialtyAntithrombin IIICoronary DiseaseStable anginaAngina PectorisFibrin Fibrinogen Degradation ProductsCoronary artery diseaseThrombinAntigenDiabetes mellitusInternal medicinemedicineHumanscardiovascular diseasesAgedbusiness.industryFibrinolysisPlasminogen activator inhibitor antigenAntithrombinFibrinogenHematologyGeneral MedicineMiddle Agedmedicine.diseaseObesityPlasminogen InactivatorsEndocrinologyDiabetes Mellitus Type 2Tissue Plasminogen ActivatorExercise TestbusinessPeptide Hydrolasesmedicine.drugBlood Coagulation & Fibrinolysis
researchProduct

Fibrinolysis in hypertriglyceridaemic subjects in response to venous occlusion.

1993

We have measured various fibrinolytic and coagulation parameters (t-PA antigen, PAI, fibrinogen, plasminogen and factor VII) before and after 10 min of venous occlusion in 20 hypertryglyceridaemic subjects (twelve males and eight females, age 38 +/- 4 years, body mass index 23 +/- 1.5) and 20 healthy normal subjects, matched for sex (twelve males and eight females), age (37 +/- 3.5 years) and body mass index (22.8 +/- 1.4). At rest, t-PA:Ag, PAI, fibrinogen, plasminogen and factor VII were significantly (P < 0.005) higher in hypertriglyceridaemic subjects than in normal controls. After venous occlusion, the increase in all parameters except t-PA:Ag was more marked in the patient group than …

AdultMalemedicine.medical_specialtyPathologymedicine.medical_treatmentFibrinogenHyperlipoproteinemia Type IVVeinschemistry.chemical_compoundAntigenInternal medicineOcclusionFibrinolysisPlasminogen Activator Inhibitor 1medicineHumansFactor VIIbusiness.industryFibrinolysisHypertriglyceridemiaFibrinogenPlasminogenHematologyGeneral MedicineFactor VIIMiddle Agedmedicine.diseaseConstrictionLipidsEndocrinologyApolipoproteinsCoagulationchemistryTissue Plasminogen ActivatorFemalebusinessBody mass indexmedicine.drugBlood coagulationfibrinolysis : an international journal in haemostasis and thrombosis
researchProduct